Any 0 3 0 3 O
medical 4 11 4 11 O
or 12 14 12 14 O
psychological 15 28 15 28 B-chronic_disease
condition 29 38 29 38 I-chronic_disease
or 39 41 39 41 O
situation 42 51 42 51 O
deemed 52 58 52 58 O
by 59 61 59 61 O
the 62 65 62 65 O
PI 66 68 66 68 O
to 69 71 69 71 O
put 72 75 72 75 O
the 76 79 76 79 O
patient 80 87 80 87 O
at 88 90 88 90 O
increased 91 100 91 100 O
risk 101 105 101 105 O
of 106 108 106 108 O
complications 109 122 109 122 O
or 123 125 123 125 O
noncompliance 126 139 126 139 O

Any 0 3 140 143 O
significant 4 15 144 155 O
organ 16 21 156 161 B-chronic_disease
impairment 22 32 162 172 I-chronic_disease
should 33 39 173 179 O
be 40 42 180 182 O
discussed 43 52 183 192 O
with 53 57 193 197 O
the 58 61 198 201 O
Study 62 67 202 207 O
Chair 68 73 208 213 O
prior 74 79 214 219 O
to 80 82 220 222 O
patient 83 90 223 230 O
entry 91 96 231 236 O

Have 0 4 237 241 O
undergone 5 14 242 251 O
a 15 16 252 253 O
prior 17 22 254 259 B-treatment
allogeneic 23 33 260 270 I-treatment
BMT 34 37 271 274 I-treatment

Hepatitis 0 9 275 284 B-chronic_disease
B 10 11 285 286 I-chronic_disease
surface 12 19 287 294 O
antigen 20 27 295 302 O
( 28 29 303 304 O
+ 29 30 304 305 O
) 30 31 305 306 O
or 32 34 307 309 O
Hepatitis 35 44 310 319 B-chronic_disease
C 45 46 320 321 I-chronic_disease
positive 47 55 322 330 O
in 56 58 331 333 O
preceding 59 68 334 343 O
six 69 72 344 347 B-upper_bound
months 73 79 348 354 I-upper_bound

Patients 0 8 355 363 O
for 9 12 364 367 O
who 13 16 368 371 O
CEM 17 20 372 375 B-treatment
( 21 22 376 377 I-treatment
carboplatin 22 33 377 388 I-treatment
, 33 34 388 389 I-treatment
etoposide 35 44 390 399 I-treatment
, 44 45 399 400 I-treatment
melphalan 46 55 401 410 I-treatment
) 55 56 410 411 I-treatment
therapy 57 64 412 419 I-treatment
is 65 67 420 422 O
administered 68 80 423 435 O
within 81 87 436 442 O
30 88 90 443 445 B-upper_bound
days 91 95 446 450 I-upper_bound
prior 96 101 451 456 I-upper_bound
to 102 104 457 459 O
131I 105 109 460 464 B-treatment
- 109 110 464 465 I-treatment
MIBG 110 114 465 469 I-treatment
therapy 115 122 470 477 I-treatment
or 123 125 478 480 O
for 126 129 481 484 O
whom 130 134 485 489 O
this 135 139 490 494 O
therapy 140 147 495 502 O
is 148 150 503 505 O
planned 151 158 506 513 O
within 159 165 514 520 O
30 166 168 521 523 O
days 169 173 524 528 O
following 174 183 529 538 O
administration 184 198 539 553 O
of 199 201 554 556 O
131I 202 206 557 561 O
- 206 207 561 562 O
MIBG 207 211 562 566 O

Patients 0 8 567 575 O
for 9 12 576 579 O
whom 13 17 580 584 O
busulfan/ 18 27 585 594 B-treatment
melphalan 28 37 595 604 I-treatment
consolidation 38 51 605 618 I-treatment
therapy 52 59 619 626 I-treatment
following 60 69 627 636 O
treatment 70 79 637 646 B-treatment
with 80 84 647 651 I-treatment
131I 85 89 652 656 I-treatment
- 89 90 656 657 I-treatment
MIBG 90 94 657 661 I-treatment
is 95 97 662 664 O
planned 98 105 665 672 O

Patients 0 8 673 681 O
must 9 13 682 686 O
have 14 18 687 691 O
a 19 20 692 693 O
Lansky 21 27 694 700 B-clinical_variable
Play 28 32 701 705 I-clinical_variable
Scale17 33 40 706 713 I-clinical_variable
of 41 43 714 716 O
60 44 46 717 719 B-upper_bound
% 46 47 719 720 I-upper_bound
( 48 49 721 722 O
< 49 50 722 723 O
16 50 52 723 725 O
yrs 53 56 726 729 O
old 57 60 730 733 O
) 60 61 733 734 O
, 61 62 734 735 O
Karnofsky 63 72 736 745 B-clinical_variable
score 73 78 746 751 I-clinical_variable
60 79 81 752 754 O
% 81 82 754 755 O
( 83 84 756 757 O
> 84 85 757 758 O
16 85 87 758 760 O
yrs 88 91 761 764 O
old 92 95 765 768 O
) 95 96 768 769 O
, 96 97 769 770 O
or 98 100 771 773 O
ECOG 101 105 774 778 B-clinical_variable
score 106 111 779 784 I-clinical_variable
of 112 114 785 787 O
< 115 116 788 789 O
or 117 119 790 792 O
equal 120 125 793 798 O
to 126 128 799 801 O
2 129 130 802 803 B-upper_bound
and 131 134 804 807 O
a 135 136 808 809 O
life 137 141 810 814 B-clinical_variable
expectancy 142 152 815 825 I-clinical_variable
of 153 155 826 828 O
2 156 157 829 830 B-upper_bound
months 158 164 831 837 I-upper_bound

Patients 0 8 838 846 O
must 9 13 847 851 O
have 14 18 852 856 O
evidence 19 27 857 865 O
of 28 30 866 868 O
MIBG 31 35 869 873 B-treatment
avid 36 40 874 878 O
disease 41 48 879 886 O
as 49 51 887 889 O
determined 52 62 890 900 O
by 63 65 901 903 O
diagnostic 66 76 904 914 O
MIBG 77 81 915 919 B-treatment
scan 82 86 920 924 I-treatment
obtained 87 95 925 933 O
within 96 102 934 940 O
4 103 104 941 942 B-upper_bound
weeks 105 110 943 948 I-upper_bound
of 111 113 949 951 O
study 114 119 952 957 O
entry 120 125 958 963 O

Patients 0 8 964 972 O
who 9 12 973 976 O
are 13 16 977 980 O
on 17 19 981 983 O
hemodialysis 20 32 984 996 B-treatment

Patients 0 8 997 1005 O
with 9 13 1006 1010 O
an 14 16 1011 1013 O
active 17 23 1014 1020 B-chronic_disease
infection 24 33 1021 1030 I-chronic_disease
requiring 34 43 1031 1040 O
intravenous 44 55 1041 1052 O
antivirals 56 66 1053 1063 B-treatment
, 66 67 1063 1064 O
antibiotics 68 79 1065 1076 B-treatment
or 80 82 1077 1079 O
antifungals 83 94 1080 1091 B-treatment

Patients 0 8 1092 1100 O
with 9 13 1101 1105 O
curative 14 22 1106 1114 B-treatment
treatment 23 32 1115 1124 I-treatment
options 33 40 1125 1132 O

Patients 0 8 1133 1141 O
with 9 13 1142 1146 O
de 14 16 1147 1149 O
novo 17 21 1150 1154 O
high 22 26 1155 1159 O
risk 27 31 1160 1164 O
neuroblastoma 32 45 1165 1178 B-cancer
who 46 49 1179 1182 O
have 50 54 1183 1187 O
completed 55 64 1188 1197 O
standard 65 73 1198 1206 O
induction 74 83 1207 1216 B-treatment
therapy 84 91 1217 1224 I-treatment
and 92 95 1225 1228 O
do 96 98 1229 1231 O
not 99 102 1232 1235 O
achieve 103 110 1236 1243 O
a 111 112 1244 1245 O
CR 113 115 1246 1248 O
, 115 116 1248 1249 O
VGPR 117 121 1250 1254 O
, 121 122 1254 1255 O
or 123 125 1256 1258 O
PR 126 128 1259 1261 O
with 129 133 1262 1266 O
low 134 137 1267 1270 O
Curie 138 143 1271 1276 O
score 144 149 1277 1282 O
post 150 154 1283 1287 O
induction 155 164 1288 1297 O

Patients 0 8 1298 1306 O
with 9 13 1307 1311 O
disease 14 21 1312 1319 O
of 22 24 1320 1322 O
any 25 28 1323 1326 O
major 29 34 1327 1332 O
organ 35 40 1333 1338 O
system 41 47 1339 1345 O
that 48 52 1346 1350 O
would 53 58 1351 1356 O
compromise 59 69 1357 1367 O
their 70 75 1368 1373 O
ability 76 83 1374 1381 O
to 84 86 1382 1384 O
withstand 87 96 1385 1394 B-treatment
therapy 97 104 1395 1402 I-treatment

Patients 0 8 1403 1411 O
with 9 13 1412 1416 O
known 14 19 1417 1422 O
MIBG 20 24 1423 1427 B-treatment
avid 25 29 1428 1432 O
brain 30 35 1433 1438 B-cancer
metastasis 36 46 1439 1449 I-cancer

Pregnancy 0 9 1450 1459 B-pregnancy

Prior 0 5 1460 1465 B-treatment
total 6 11 1466 1471 I-treatment
body 12 16 1472 1476 I-treatment
irradiation 17 28 1477 1488 I-treatment
, 28 29 1488 1489 O
prior 30 35 1490 1495 B-treatment
total 36 41 1496 1501 I-treatment
abdominal 42 51 1502 1511 I-treatment
or 52 54 1512 1514 O
whole 55 60 1515 1520 B-treatment
liver 61 66 1521 1526 I-treatment
radiation 67 76 1527 1536 I-treatment

The 0 3 1537 1540 O
presence 4 12 1541 1549 O
of 13 15 1550 1552 O
mixed 16 21 1553 1558 O
response 22 30 1559 1567 O
( 31 32 1568 1569 O
MR 32 34 1569 1571 O
) 34 35 1571 1572 O
, 35 36 1572 1573 O
or 37 39 1574 1576 O
no 40 42 1577 1579 O
response 43 51 1580 1588 O
( 52 53 1589 1590 O
NR 53 55 1590 1592 O
) 55 56 1592 1593 O
following 57 66 1594 1603 O
the 67 70 1604 1607 O
completion 71 81 1608 1618 O
of 82 84 1619 1621 O
A3973 85 90 1622 1627 O
or 91 93 1628 1630 O
equivalent 94 104 1631 1641 O
induction 105 114 1642 1651 B-treatment
therapy 115 122 1652 1659 I-treatment

the 0 3 1660 1663 O
presence 4 12 1664 1672 O
of 13 15 1673 1675 O
a 16 17 1676 1677 O
partial 18 25 1678 1685 O
response 26 34 1686 1694 O
( 35 36 1695 1696 O
PR 36 38 1696 1698 O
) 38 39 1698 1699 O
with 40 44 1700 1704 O
high 45 49 1705 1709 O
Curie 50 55 1710 1715 B-clinical_variable
score 56 61 1716 1721 I-clinical_variable
( 62 63 1722 1723 O
> 63 64 1723 1724 O
2 64 65 1724 1725 B-lower_bound
) 65 66 1725 1726 O
following 67 76 1727 1736 O
induction 77 86 1737 1746 B-treatment
therapy 87 94 1747 1754 I-treatment

